V WHO Operational Tool for efficient and effective lot release of SARS-CoV-2 (Covid-19) vaccines PDF Guideline/guidance
V WHO Package Leaflet - BioNtech Tozinameran – COVID-19 mRNA vaccine (nucleoside modified) - Grey Cap PDF Guideline/guidance
V WHO Package Leaflet - BioNtech Tozinameran – COVID-19 mRNA vaccine (nucleoside modified) - Orange Cap PDF Guideline/guidance
V WHO Package Leaflet - BioNtech Tozinameran – COVID-19 mRNA vaccine (nucleoside modified) - Purple Cap PDF Guideline/guidance
V WHO Product Characteristics - BioNtech Tozinameran – COVID-19 mRNA vaccine (nucleoside modified) – Grey Cap PDF Guideline/guidance
V WHO Product Characteristics - BioNtech Tozinameran – COVID-19 mRNA vaccine (nucleoside modified) – Orange Cap PDF Guideline/guidance
V WHO Product Characteristics - BioNtech Tozinameran – COVID-19 mRNA vaccine (nucleoside modified) – Purple Cap PDF Guideline/guidance
V WHO Product Information - BioNtech – COVID-19 mRNA vaccine (nucleoside modified) – COMIRNATY PDF Guideline/guidance
V WHO Product Information - Moderna COVID-19 mRNA Vaccine (nucleoside modified) PDF Guideline/guidance
V WHO Product Leaflet for Health Workers - Serum Institute of India Pvt Ltd - COVID-19 Vaccine (ChAdOx1-S [recombinant]) - COVISHIELD PDF
V WHO Recommendation for EUL of AZD1222 submitted by AstraZeneca AB and manufactured by SK Bioscience Co Ltd. (Published: 23 February 2021) PDF Guideline/guidance
V WHO Recommendation for EUL of COVISHIELD™ submitted by Serum Institute of India Pvt Ltd PDF Guideline/guidance
V WHO Summary of Product Characteristics - BioNtech Tozinameran – COVID-19 mRNA vaccine (nucleoside modified) - Orange Cap PDF Guideline/guidance
V WHO workshop on implementation of good manufacturing practices for biological products, Seoul, September 2018 PDF Report